Documentaries, videos and podcasts
December 3, 2019
Salv, an anti-money laundering (AML) startup founded by former TransferWise and Skype employees, has raised $2 million in seed funding. The round is led by Fly Ventures, alongside Passion Capital and Seedcamp. Angel investors also participating include N26 founder Maximilian Tayenthal (who seems to be doing quite a bit of angel investing), Twilio CTO Ott [...]
November 25, 2019
TookiTaki, a startup that develops machine learning-based financial compliance software, announced today it has raised a $11.7 million in additional Series A funding, led by Viola Fintech and SIG Asia Investment, with participation from Normura Holdings. Existing investors Illuminate Financial, Jungle Ventures and SEEDs Capital also returned for the extension, which brings TookiTaki's total Series [...]
September 17, 2019
LONDON, Sept. 17, 2019 /PRNewswire/ -- Wealth management firms globally are struggling to onboard new clients within four weeks for a standard High Net Worth...
Actinium Pharmaceuticals, Inc.
September 16, 2019
NEW YORK, Sept. 16, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will present at the Sachs...
August 28, 2019
Read more about Sebi inquiry clears Sun Pharma, finds no merit in allegations of fraud on Business Standard. The investigation team is of the view that the matter does not require further probe, said sources. The team sent its report to the Sebi committee for vetting
May 15, 2019
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced the publication of a study demonstrating the power of its Tapestri® Platform to help predict and prevent cancer progression. The study, published in Cancer Discovery, is the first-ever study using single-cell DNA analysis to reveal how cancer evolves in response to targeted treatment, leading to therapy resistance and disease progression in AML patients., , , , Although new ta...
May 7, 2019
SAN DIEGO, May 7, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to...
April 30, 2019
DUBLIN and DUBAI, UAE, April 30, 2019 /PRNewswire/ -- Fenergo, the leading provider of digital Client Lifecycle Management (CLM) solutions for financial...
Innovative Systems, Inc.
April 22, 2019
PITTSBURGH, 22 de abril de 2019 /PRNewswire/ -- Dados de má qualidade representam grandes desafios para uma triagem de conformidade bem-sucedida no combate à...
SAN DIEGO, Feb. 14, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach...
LONDON, Feb. 13. 2019 /PRNewswire/ -- Fenergo, the leading provider of digital Client Lifecycle Management (CLM) software solutions for financial institutions, ...
Astellas Pharma Inc.
TOKYO, Dec. 10, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "Astellas") today announced that XOSPATA®...
December 10, 2018
Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, announced that it has been selected by Astellas Pharma US, Inc. to be in the limited distribution network for XOSPATA® (gilteritinib). XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory Acute Myeloid Leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test. XOSPATA was approved by the U.S. Food and Dr...
December 4, 2018
, , , , • Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in a retrospective analysis of US electronic health records , , , , • Patients who received splenectomy, as second-line regimen, showed highest platelet counts and most frequent thrombotic event rates among groups receiving other therapies , , , , • Immune thrombocytopenia (ITP) is a rare blood disorder where there is an increased risk of...